Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma (DREAM)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01000506
First received: October 22, 2009
Last updated: September 19, 2013
Last verified: November 2012

October 22, 2009
September 19, 2013
November 2009
December 2011   (final data collection date for primary outcome measure)
Frequency of clinically significant exacerbations of asthma [ Time Frame: 52-weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01000506 on ClinicalTrials.gov Archive Site
  • Time to first clinically significant exacerbation requiring oral or systemic corticosteroids, hospitalisation, and/or ED visits [ Time Frame: 52-weeks ] [ Designated as safety issue: No ]
  • Frequency of exacerbations requiring hospitalization (including intubation and admittance to an ICU) or ED visits [ Time Frame: 52-weeks ] [ Designated as safety issue: No ]
  • Time to first exacerbation requiring hospitalization or ED visit [ Time Frame: 52-weeks ] [ Designated as safety issue: No ]
  • Frequency of investigator-defined exacerbations [ Time Frame: 52-weeks ] [ Designated as safety issue: No ]
  • Time to first investigator-defined exacerbation [ Time Frame: 52-weeks ] [ Designated as safety issue: No ]
  • Mean change from baseline in clinic pre-bronchodilator FEV1 over the 52-week treatment period [ Time Frame: 52-weeks ] [ Designated as safety issue: No ]
  • Mean change from baseline in clinic post-bronchodilator FEV1 over the 52 week treatment period [ Time Frame: 52-weeks ] [ Designated as safety issue: No ]
  • Mean change from baseline in Asthma Control Questionnaire (ACQ) score [ Time Frame: 52-weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects With Severe Uncontrolled Refractory Asthma

The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma medications. The study will look at different doses of mepolizumab in comparison to a placebo.

A double-blind, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of three doses (75 mg, 250 mg and 750 mg) of mepolizumab intravenous (i.v.) administered every 4 weeks compared with placebo over a 52-week treatment period in subjects with severe uncontrolled refractory asthma. Efficacy will be measured by the frequency of asthma exacerbations. In addition lung function, rescue medication usage, daily symptoms, asthma control score, asthma quality of life score and withdrawals due to asthma exacerbations will be assessed. Safety will be assessed by adverse events, clinical laboratory evaluations, ECGs, immunogenicity and vital signs. Pharmacodynamics will be assessed by eosinophil levels in blood, serum IL-5 and eosinophil levels in induced sputum.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Asthma
Biological: Mepolizumab (treatment) - Severe asthma
Mepolizumab 750mg, 250mg or 75mg every four weeks i.v.
  • Active Comparator: Mepolizumab 750mg
    Mepolizumab 750mcg i.v. every 4 weeks
    Intervention: Biological: Mepolizumab (treatment) - Severe asthma
  • Active Comparator: Mepolizumab 250mg
    Mepolizumab 250mcg i.v. every 4 weeks
    Intervention: Biological: Mepolizumab (treatment) - Severe asthma
  • Active Comparator: Mepolizumab 75mg
    Mepolizumab 75mcg i.v. every 4 weeks
    Intervention: Biological: Mepolizumab (treatment) - Severe asthma
  • Placebo Comparator: Placebo
    Placebo saline every 4 weeks i.v.
    Intervention: Biological: Mepolizumab (treatment) - Severe asthma
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 Aug 18;380(9842):651-9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
621
March 2012
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female
  • Aged 12 to 65 years inclusive
  • Minimum weight 45kg
  • Clinical features of severe refractory asthma
  • Well documented requirement for high dose inhaled corticosteroids (ICS) [i.e. >= 880mcg/day fluticasone propionate or equivalent daily] for at least 12 months
  • Using additional controller medication in addition to high dose ICS for at least 12 months
  • Persistent airflow obstruction indicated by a pre-bronchodilator FEV1<80% predicted at visit 1 or 2 or peak flow diurnal variability of >20% on 3 or more days during the run-in
  • Airway inflammation which is likely to be eosinophilic in nature demonstrated by either raised peripheral blood eosinophils (>=300/microL), sputum eosinophils (>=3%), exhaled nitric oxide (>=50ppb) or prompt deterioration of asthma control following a <=25% reduction in regular maintenance dose of inhaled or oral corticosteroids (OCS)
  • History of 2 or more exacerbations requiring systemic corticosteroids in the previous 12 months
  • Evidence of asthma documented by airway reversibility, airway hyperresponsiveness or airflow variability
  • ECG assessment demonstrating QTc<450msec or QTc<480msec for patients with bundle branch block
  • Liver function tests demonstrating ALT<2xUpper Limit of Normal (ULN), AST<2xULN, Alk Phos <=1.5xULN, bilirubin <=1.5xULN
  • Female of non-child-bearing potential or child-bearing potential with a negative pregnancy test at screening and prepared to agree to an acceptable method of contraception
  • Able to give written informed consent
  • Able to read, comprehend and write at a sufficient level to complete study materials

Exclusion Criteria:

  • Current smokers or smoking history of >=10 pack years
  • Clinically important lung condition other than asthma
  • Diagnosis of malignancy or in the process of investigation
  • Unstable liver disease
  • Churg-Strauss syndrome
  • Using methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine or any experimental anti-inflammatory therapy within 3 months of screening
  • Omalizumab (Xolair) or any other biological for the treatment of inflammatory disease within 6 months of Visit 1
  • Regular use of oral or systemic corticosteroids for diseases other than asthma within 12 months or any intra-articular, short-acting intramuscular corticosteroid within 1 month or intramuscular, long-acting depot corticosteroid within 3 months
  • Allergy/intolerance to the excipients in the mepolizumab formulation
  • Any investigational drug within 30 days or 5 terminal half-lives, whichever is longer
  • Pregnant or breastfeeding or planning to become pregnant
  • Clinically significant disease which is uncontrolled with standard treatment
  • History of alcohol misuse or substance abuse
  • Parasitic infestation within previous 6 months
  • Known immunodeficiency
  • Unable to follow instructions, use the electronic diary or peak flow meter
  • Known evidence of lack of adherence to controller medications and/or follow physician's recommendations
  • Previous participation in a study of mepolizumab and received study medication within 90 days
Both
12 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Argentina,   Australia,   Canada,   Chile,   France,   Germany,   Korea, Republic of,   Poland,   Romania,   Russian Federation,   Ukraine,   United Kingdom
 
NCT01000506
112997
No
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP